Abstract:Poster session 1, September 21, 2022, 12:30 PM - 1:30 PMObjectivesFluconazole is widely used to treat invasive fungal infections, but the fluconazole resistance of pathogenic fungi undermines its antifungal efficacy. Although voriconazole has a good anti- Aspergillus fumigatus activity, it is not a first-line drug for treating infections caused by Candida and Cryptococcus species. To meet the demand for new azoles, in our previous studies, we identified a new azoles compound, YZJT-1903 (Fig. 1e), and found that YZJT-1903 has a longer in vivo half-life (˃10 days in rat) and a wider therapeutic window than voriconazole, indicating that YZJT-1903 is a promising azoles compound to treat invasive fungal infections. In this study, we further investigated antifungal activity of YZJT-1903 compared with fluconazole and voriconazole.MethodsWe investigated the antifungal spectrum of YZJT-1903 and minimum inhibitory concentration (MIC) and accumulative antifungal percentage of YZJT-1903 against various pathogenic fungi using microbroth dilution method. We quantitatively analyzed the inhibitory effect of YZJT-1903 on fungal growth by the Time-Growth Curve assay. Mutation Preventative Concentration (MPC) was carried out to verify the antifungal potential of YZJT-1903. Sterols of plasma membrane were extracted and the composition was analyzed through Gas Chromatograph-Mass Spectrometer (GC-MS) to verify the classical action mechanism of azoles.ResultsOur MIC assay results demonstrated that YZJT-1903 has a broad antifungal spectrum and can significantly inhibit the growth of A. fumigatus, Cryptococcus neoformans, Cryptococcus gatti , and Candida species (such as Candida albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. guilliermondii , and C. auris ) (Fig. 1a). We found that the antifungal activity of YZJT-1903 is equivalent to that of voriconazole, but superior to that of fluconazole (Fig. 1a). Accumulative antifungal percentage can directly reflect this relationship quantitatively among YZJT-1903, fluconazole, and voriconazole due to the curve of YZJT-1903 has no significance with voriconazole (Fig. 1b). YZJT-1903 (0.25 μ g/ml) has similar inhibitory effect to voriconazole (0.25 μ g/ml) on the growth of C. albicans and C. neoformans , but has the best inhibitory effect on C. auris [compared with voriconazole (0.25 μ g/ml), and fluconazole (0.25 μ g/ml)] (Fig. 1c). MPC of YZJT-1903 in C. neoformans is as low as 0.25 μ g/ml which means YZJT-1903 at low concentration can already prevent the drug-resistant mutation of strains, therefore, avoid the occurrence of resistance in Cryptococcus spp. (Fig. 1d). Extraction of sterols showed that the fungal cell treated with YZJT-1903 at 0.063 μ g/ml have completely no detectable ergosterol which is similar to the group of fluconazole at 4 μ g/ml, and the group of voriconazole at 0.031 μ g/ml (Fig. 2). This result gave a hint that maybe the property of YZJT-1903 is more similar to voriconazole which may matter with the structure of these two compounds. We found that feeding exogenous 100 μ m ergosterol counteracted the antifungal activity of YZJT-1903, indicating that YZJT-1903 has an antifungal activity by inhibiting the synthesis of ergosterol.ConclusionOur study demonstrates that YZJT-1903 has a potent antifungal activity, which will contribute to addressing devastating global invasive fungal infections caused by Candida and Cryptococcus species.

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

In Vitro Antifungal Activity of Micafungin and Caspofungin Against Dermatophytes Isolated from China

In vitro antifungal susceptibility profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group (ECIFIG)

Preliminary study on the susceptibility of a polyene-resistant Aspergillus flavus strain to common antifungal drugs

In vitro activities of nine antifungal agents against rare pathogenic fungi.

Susceptibility testing of Aspergillus biofilms against common antifungal drugs and a preliminary study on molecular mechanisms of antifungal drug resistance in Aspergillus biofilms

Antifungal susceptibility testing of clinical isolates of itraconazole-resistant Aspergillus fumigatus to four antifungal drugs

Antifungal susceptibility test for pathogenic Fusarium spp in vitro

In Vitro Antifungal Activity of Caspofungin and Micafungin Against 8 Species of Dermatophyte

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

P063 Research on antifungal activity of a new azoles compound, YZJT-1903

MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp

Antifungal Susceptibility Testing of 100 Clinical Isolates of Pathogenic Yeasts

Efficacy and Safety of Micafungin for the Treatment of Patients with Proven or Probable Invasive Aspergillosis: A Non-Comparative, Multicenter, Phase IV, Open-Label Study.

In Vitro Activities of Five Antifungal Agents Against Pathogenic Exophiala Species

Comparison of susceptibility testing by EUCAST and CLSI broth microdilution methods against Aspergillus isolates

A 20-Year Antifungal Susceptibility Surveillance (from 1999 to 2019) for Aspergillus Spp. and Proposed Epidemiological Cutoff Values for Aspergillus Fumigatus and Aspergillus Flavus: A Study in a Tertiary Hospital in China